$IDXG On a Clear Breakout with Potential News Down Pipeline
IDXG Latest Insider Purchases, Institutional Ownerships and News: 2016-02-03 Glorikian Harry Director Acquired 127,696
2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696
2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756
2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656
2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired 965,784
John P. Dugan (Founder): 4,869,878 common shares
Other Insiders Approximately: 2,672,149 shares collectively
Total Insiders: 7,542,027 shares
Institutional Ownership: 30.6% 5.5 mil shares (Increased to 6.5 mil as of June 23rd)
Largest Institutional Holder: Heartland Advisors: 2,994,313
Recent News Headlines:
2017-06-28 Interpace Diagnostics Announces National Contract With Aetna
2017-06-26 Interpace Diagnostics Announces Coverage Of Thyroid Test By Premera Blue Cross
2017-06-16 Interpace Diagnostics Announces Pricing Of $13.7 Million Underwritten Public Offering Of Common Stock And Common Warrants
2017-06-06 Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia
2017-05-25 Interpace Diagnostics Announces Launch Of Enhancement To Thyroid Testing Services
2017-05-16 Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q1 2017 Results - Earnings Call Transcript
2017-05-15 Interpace Diagnostics To Host Conference Call And Webcast To Discuss First Quarter 2017 Financial Results On Monday May 15, 2017
2017-05-10 Interpace Diagnostics Presents New Data on PancraGEN® at DDW
2017-04-20 Interpace Diagnostics Eliminates Long Term Secured Debt
2017-04-18 Interpace Diagnostics Announces Coverage Of ThyraMIR With UnitedHealthcare
2017-04-13 Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement
2017-04-04 A Look at Interpace Diagnostics Financials, Drug Pipeline and Market Opportunity
2017-04-03 Interpace Diagnostics Announces European Patent Approval For Underlying Technology Of Its Thyramir Microrna Classifier
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.